Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Product › Details


Products Next higher product group durvalumab (MEDI4736, anti-PD-L1 antibody)
Period Status 2017-05-01 registration start
Organisation Organisation MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
Document Source AstraZeneca plc. (5/1/17). "Press Release: AstraZeneca’s Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer".

Record changed: 2018-04-28


Picture [LSF] – The Business Web Portal 600x80px

More documents for Imfinzi®

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2018 Boston September 600x60px

» top